Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.

Strong uniform expression of FOXP1 protein occurs in a subgroup of non-germinal centre (GC) diffuse large B-cell lymphomas (DLBCL). We have investigated gene rearrangement as a potential mechanism for deregulated expression of FOXP1 however, using FISH FOXP1 translocations were not found in any case...

Full description

Bibliographic Details
Main Authors:	Barrans, S, Fenton, J, Ventura, R, Smith, A, Banham, A, Jack, A
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
by: Barrans, S, et al.
Published: (2004)

Strong expression of FOXP1 predicts for poor prognosis within the non-germinal centre subgroup of diffuse large B cell lymphoma
by: Barrans, S, et al.
Published: (2005)

t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.
by: Fenton, J, et al.
Published: (2006)

The significance of FOXP1 in diffuse large B-cell lymphoma
by: Gascoyne, D, et al.
Published: (2016)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
by: Haralambieva, E, et al.
Published: (2006)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
by: Camilleri, E, et al.
Published: (2012)

FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control
by: Goatly, A, et al.
Published: (2008)

FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
by: Goatly, A, et al.
Published: (2008)

Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
by: Brown, P, et al.
Published: (2008)

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
by: Banham, A, et al.
Published: (2005)

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
by: Nyman, H, et al.
Published: (2009)

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
by: Nyman, H, et al.
Published: (2008)

Is FOXP3 expressed in cutaneous T-cell lymphomas?
by: Banham, A, et al.
Published: (2008)

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
by: Wong, K, et al.
Published: (2016)

MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
by: Borovecki, A, et al.
Published: (2007)

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.
by: Minna Taskinen, et al.
Published: (2014-01-01)

FOXP3 expression in B and T cell lymphomas.
by: Roncador, G, et al.
Published: (2005)

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
by: Brown, P, et al.
Published: (2015)

The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.
by: Brown, P, et al.
Published: (2005)

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
by: Brown, P, et al.
Published: (2016)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
by: Liggins, A, et al.
Published: (2004)

A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma.
by: Matthew A Care, et al.
Published: (2013-01-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
by: Banham, A, et al.
Published: (2009)

The FOXP3 transcription factor as a regulatory T-cell marker
by: Banham, A
Published: (2008)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
by: Wong, K, et al.
Published: (2014)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
by: Wong, K, et al.
Published: (2014)

FOXP3+ regulatory T cells as biomarkers in human malignancies.
by: Bignone, P, et al.
Published: (2008)

FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma.
by: Roncador, G, et al.
Published: (2005)

The architectural pattern of FOXP3(+) T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
by: Farinha, P, et al.
Published: (2006)

The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
by: Farinha, P, et al.
Published: (2006)

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
by: A. V. de Jonge, et al.
Published: (2024-01-01)

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications
by: Dima El-Sharkawi, et al.
Published: (2023-04-01)

Does CBD induce apoptosis in diffuse large B cell lymphoma?
by: Xu, S.
Published: (2018-08-01)

CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model
by: Felce, SL, et al.
Published: (2020)

Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species.
by: Banham, A, et al.
Published: (2009)

Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis
by: Jing Yang, et al.
Published: (2022-09-01)

P120: Novel genomic rearrangement leading to MYC over expression in the genomic setting of a pseudo-triple-hit diffuse large B-cell lymphoma
by: Ramakrishna Koduru, et al.
Published: (2024-01-01)

Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.
by: Banham, A
Published: (2006)

Pathway activation patterns in diffuse large B-cell lymphomas.
by: Bentink, S, et al.
Published: (2008)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
by: F. Morschhauser, et al.
Published: (2022-06-01)